68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

Isabel Rauscher, Tobias Maurer, Wolfgang P. Fendler, Wieland H. Sommer, Markus Schwaiger, Matthias Eiber

Research output: Contribution to journalReview articlepeer-review

160 Scopus citations

Abstract

Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.

Original languageEnglish
Article number14
JournalCancer Imaging
Volume16
Issue number1
DOIs
StatePublished - 8 Jun 2016
Externally publishedYes

Keywords

  • Positron emission tomography
  • Prostate cancer
  • Prostate specific membrane antigen

Fingerprint

Dive into the research topics of '68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report'. Together they form a unique fingerprint.

Cite this